By deacetylating and activating protein kinase B (AKT), it can enhance EMT to target the AKT/GSK3β/β-catenin signaling pathway in hepatocellular carcinoma [43] and promote the migration and invasion of gastric cancer through the RAS/ERK/JNK/MMP-9 pathway [44]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.